Antiviral Drugs - Moldova

Moldova

The projected revenue for the Antiviral Drugs market in Moldova is estimated to reach US$2.60m in 2024.
It is expected to exhibit an annual growth rate (CAGR 2024-2029) of 0.83%, leading to a market volume of US$2.71m by 2029.
In terms of global comparison, United States is projected to generate the highest revenue of US$30,640.00m in 2024.
Moldova has seen a surge in demand for antiviral drugs due to its vulnerable healthcare system and high prevalence of infectious diseases.

Key regions: Brazil, India, Australia, United States, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

Antiviral drugs have become increasingly important in the healthcare sector due to the rise of viral infections. Moldova, a small country in Eastern Europe, has also witnessed a significant increase in the demand for antiviral drugs in recent years.

Customer preferences: Moldovan customers prefer antiviral drugs that are effective and affordable. They also tend to choose drugs that have minimal side effects. Customers in Moldova are also open to alternative medicine and traditional remedies.

Trends in the market: The antiviral drugs market in Moldova has been growing steadily due to the increasing incidence of viral infections. The COVID-19 pandemic has further accelerated the growth of the market. The demand for antiviral drugs has increased significantly due to the pandemic. The market has also witnessed the introduction of new antiviral drugs in recent years. Generic drugs are also becoming increasingly popular due to their affordability.

Local special circumstances: Moldova has a high incidence of viral infections due to its geographic location and climate. The country is also one of the poorest in Europe, which has led to a high demand for affordable antiviral drugs. The healthcare system in Moldova is also underfunded and lacks resources, which has led to a reliance on generic drugs. The country also has a large population of elderly people who are more susceptible to viral infections.

Underlying macroeconomic factors: Moldova's economy has been growing slowly in recent years, which has led to a rise in the demand for affordable healthcare. The government has also been investing in the healthcare sector to improve access to healthcare for its citizens. The rise of viral infections has also led to an increase in healthcare spending. The country's accession to the European Union has also led to an increase in foreign investment in the healthcare sector.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.